Core Insights - The National Medical Products Administration of China announced that by 2025, 76 innovative drugs have been approved for market, surpassing the 48 approved in 2024, marking a historical high [1] - The total value of authorized transactions for innovative drugs in China exceeded $130 billion in 2025, with over 150 transactions, also a historical high [1] Summary by Category Innovative Drug Approvals - In 2025, 76 innovative drugs were approved, consisting of 47 chemical drugs, 23 biological products, and 6 traditional Chinese medicines [1] - Among the 47 chemical drugs, 38 are domestic innovations and 9 are imported, with domestic innovations accounting for 80.85% [1] - For the 23 biological products, 21 are domestic innovations and 2 are imported, with domestic innovations making up 91.30% [1] Industry Positioning - The approval of these innovative drugs signifies a transition in China's biopharmaceutical sector from following to keeping pace, and in some areas, leading the global market [1] - This development indicates that China has become a significant player in the global biopharmaceutical innovation landscape [1]
2025年我国 有76个创新药获批上市
Xin Lang Cai Jing·2026-01-07 17:12